[go: up one dir, main page]

EA200800780A1 - Производные пиримидина и их применение в качестве открывателей калиевых каналов kcnq - Google Patents

Производные пиримидина и их применение в качестве открывателей калиевых каналов kcnq

Info

Publication number
EA200800780A1
EA200800780A1 EA200800780A EA200800780A EA200800780A1 EA 200800780 A1 EA200800780 A1 EA 200800780A1 EA 200800780 A EA200800780 A EA 200800780A EA 200800780 A EA200800780 A EA 200800780A EA 200800780 A1 EA200800780 A1 EA 200800780A1
Authority
EA
Eurasian Patent Office
Prior art keywords
openers
pyrimidine derivatives
application
potassium channel
kcnq potassium
Prior art date
Application number
EA200800780A
Other languages
English (en)
Inventor
Николай Ханжин
Даниель Родригез Греве
Марио Роттлендер
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA200800780A1 publication Critical patent/EA200800780A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к производным пиримидина общей формулы I или их солям и их применению в качестве открывателей калиевых ионных каналов семейства KCNQ, предпочтительно, при лечении эпилепсии.
EA200800780A 2005-09-09 2006-09-07 Производные пиримидина и их применение в качестве открывателей калиевых каналов kcnq EA200800780A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200501262 2005-09-09
PCT/DK2006/050039 WO2007065449A1 (en) 2005-09-09 2006-09-07 Pyrimidine derivatives and their use as kcnq potassium channels openers

Publications (1)

Publication Number Publication Date
EA200800780A1 true EA200800780A1 (ru) 2008-06-30

Family

ID=37199174

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800780A EA200800780A1 (ru) 2005-09-09 2006-09-07 Производные пиримидина и их применение в качестве открывателей калиевых каналов kcnq

Country Status (15)

Country Link
EP (1) EP1937653A1 (ru)
JP (1) JP2009507052A (ru)
KR (1) KR20080043314A (ru)
CN (1) CN101258133A (ru)
AR (1) AR055420A1 (ru)
AU (1) AU2006322461A1 (ru)
BR (1) BRPI0615631A2 (ru)
CA (1) CA2621854A1 (ru)
EA (1) EA200800780A1 (ru)
IL (1) IL189545A0 (ru)
MX (1) MX2008002294A (ru)
NO (1) NO20081713L (ru)
UA (1) UA93387C2 (ru)
WO (1) WO2007065449A1 (ru)
ZA (1) ZA200802174B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513196A (ja) * 2007-08-01 2011-04-28 ハー・ルンドベック・アクチエゼルスカベット ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010097379A1 (en) * 2009-02-24 2010-09-02 Neurosearch A/S Substituted pyrimidin derivatives and their medical use
CA2804165C (en) * 2010-07-08 2015-02-24 Pfizer Inc. Piperidinyl pyrimidine amides as kv7 potassium channel openers
KR101820645B1 (ko) * 2010-10-20 2018-01-22 그뤼넨탈 게엠베하 Ｋｃｎｑ２／３ 조절제로서의 치환된 ６­아미노­니코틴아미드
CN103508943B (zh) * 2012-06-29 2017-06-09 江苏先声药业有限公司 作为钾通道调节剂的化合物
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
SG11201703284XA (en) * 2014-10-24 2017-06-29 Ono Pharmaceutical Co Kcnq2-5 channel activator
CN119490430A (zh) * 2019-08-02 2025-02-21 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183335A1 (en) * 2001-02-20 2002-12-05 Piyasena Hewawasam 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators
AU2003202115A1 (en) * 2002-02-12 2003-09-04 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
US20080261918A1 (en) * 2004-12-17 2008-10-23 Graham Andrew Showell Silicon Compounds and Their Use

Also Published As

Publication number Publication date
AU2006322461A1 (en) 2007-06-14
CN101258133A (zh) 2008-09-03
ZA200802174B (en) 2009-10-28
JP2009507052A (ja) 2009-02-19
EP1937653A1 (en) 2008-07-02
BRPI0615631A2 (pt) 2011-05-24
WO2007065449A1 (en) 2007-06-14
KR20080043314A (ko) 2008-05-16
AR055420A1 (es) 2007-08-22
UA93387C2 (ru) 2011-02-10
NO20081713L (no) 2008-06-04
IL189545A0 (en) 2008-06-05
CA2621854A1 (en) 2007-06-14
MX2008002294A (es) 2008-03-14

Similar Documents

Publication Publication Date Title
EA200700633A1 (ru) Производные замещённого анилина
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
EA201170521A1 (ru) Новые соединения
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA201101330A1 (ru) Замещенные пиримидины, предназначенные для лечения рака
EA200870116A1 (ru) Бициклические гетероарильные соединения
NO20082298L (no) Kaliumkanalinhibitorer
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
DK1631295T3 (da) Anvendelse af kondenserede heterocykliske forbindelser som SCCE-inhibitorer ved behandling af hudsygdomme
EA201100447A1 (ru) Органические соединения
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
EA201100794A1 (ru) Замещенные пиримидины, предназначенные для лечения заболеваний, таких как рак
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
EA201100874A1 (ru) Соединения для лечения рака
EA200700286A1 (ru) Применение замещённых производных 2-пирролидона в качестве фунгицидов и инсектицидов
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
NO20081713L (no) Pyrimidinderivater og deres anvendelse som KCNQ-kaliumkanalapnere
TW200630367A (en) Substituted adenines and the uses thereof
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
EA201001348A1 (ru) Пирролопиримидинкарбоксамиды